Preparation method of medical composition containing polyglutamic acid, medical composition and medical dressing

Abstract

The invention relates to the technical field of medical instruments, and discloses a preparation method of a medical composition containing polyglutamic acid, the medical composition and medical dress.The medical composition containing polyglutamic acid is prepared from, by mass, 0.1%-5% of sodium hyaluronate, 2%-6% of glycerin, 0.35%-0.8% of carbomer, 0.3%-3.5% of hydroxyethyl cellulose, 0.1%-5% of polyglutamic acid, 1.8%-2.5% of trehalose and the balance water. The composition comprises the following components in percentage by weight: 0.1%-1% of recombinant human collagen, 0.5%-5.0% of beta-glucan, 0.5%-1.5% of silicon nitride particles, 0.5%-1.0% of benzyl alcohol and the balance of purified water. The medical composition containing polyglutamic acid can promote wound healing, inhibit melanin formation, whiten skin and reduce pain and scar formation.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and provides a preparation method of a medical composition containing polyglutamic acid, the medical composition and a medical dressing. Background Art

[0002] With the popularization of biomedical materials and people's increasing requirements for medical products, the role of medical dressings has evolved from simple wound coverage to bioactive materials with complex functions. Ideal medical dressings should not only provide physical protection for wounds and prevent infection, but also promote wound healing and reduce pain and scar formation.

[0003] However, existing medical dressings have limited effects on wound healing, and unstable dressings may degrade or change in structure during storage, thus affecting their function and safety. Therefore, improvements are urgently needed. Summary of the invention

[0004] The present invention provides a method for preparing a medical composition. The prepared medical composition has the advantages of painlessness, mild whitening effect, lower infection risk, higher stability, and convenient use. The medical composition or medical dressing of the present invention can promote wound healing, inhibit melanin formation, whiten the skin, and reduce pain and scar formation.

[0005] The technical problem solved by the present invention is achieved by adopting the following technical solutions: In a first aspect, the present application provides a method for preparing a medical composition comprising polyglutamic acid, the method comprising: providing a first solution comprising purified water, glycerin, and carbomer; Mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and the first solution under heating conditions to obtain a third mixture; subjecting the third mixture to ultrasonic treatment and cooling at least three times to obtain a fourth mixed solution; Providing a second solution comprising purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol; The fourth mixed liquid is mixed with the second solution to obtain a medical composition, which includes, by mass percentage, the following: sodium hyaluronate: 0.1%-5%, glycerol: 2%-6%, carbomer: 0.35%-0.8%, hydroxyethyl cellulose: 0.3%-3.5%, polyglutamic acid: 0.1%-5%, trehalose: 1.8%-2.5%, recombinant human collagen: 0.1%-1%, benzyl alcohol: 0.5%-1.0%, β-glucan: 0.5%-5.0%, silicon nitride particles: 0.5%-1.5%, and the balance is purified water.

[0006] In some embodiments, the medical composition includes, by mass percentage: sodium hyaluronate: 4%, glycerol: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β-glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

[0007] In some embodiments, the mass ratio of the fourth mixed solution to the second solution is 1:(0.5-2).

[0008] In some embodiments, the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles is 5:4:(0.8-1).

[0009] In some embodiments, the medicinal composition is solvent-based.

[0010] In some embodiments, at least three ultrasonic treatments include, in sequence: a first ultrasonic treatment, a second ultrasonic treatment, and a third ultrasonic treatment; the temperature of the first ultrasonic treatment is 40-50°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 30-50kHz for 1-3min; the temperature of the second ultrasonic treatment is 50-60°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 20-25kHz for 2-5min; the temperature of the third ultrasonic treatment is 50-65°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 10-15kHz for 2-5min.

[0011] In some embodiments, the third mixture is subjected to ultrasonic treatment and cooling at least three times to obtain a fourth mixed solution, comprising: The third mixture is subjected to ultrasonic treatment at least three times, and then vacuum is turned on for defoaming, and the defoaming time is 3-10 minutes; Then the mixture is cooled to 25-30° C. to obtain a fourth mixed solution.

[0012] In some embodiments, the viscosity of the fourth mixed liquid is 100-600 cst.

[0013] In a second aspect, the present application provides a medical composition comprising polyglutamic acid, which is prepared by the preparation method of the first aspect.

[0014] In a third aspect, the present application provides a medical dressing, which is obtained by drying the medical composition prepared by the preparation method of the first aspect, wherein the medical dressing is in a gel state and has a water content of 40%-60%.

[0015] In the embodiment of the present application, polyglutamic acid is a natural biopolymer material produced by microbial fermentation, which has excellent biocompatibility and biodegradability, moisturizing and antibacterial effects; silicon nitride particles have excellent biocompatibility and safety in medical compositions, and have good antibacterial properties and biological activity; silicon nitride particles have physical pores to reduce the probability of inflammation. Benzyl alcohol is a compound with weak antibacterial properties, which can inhibit the growth of bacteria to a certain extent, reduce the risk of wound infection, and act with recombinant human collagen and β-glucan to promote wound healing and tissue repair. Benzyl alcohol is usually used as a solvent to help dissolve and stabilize other whitening active ingredients, such as human collagen and β-glucan. The medical composition can make polyglutamic acid and silicon nitride particles directly delivered to the target area, such as the wound infection, through the skin, which can provide a continuous and stable release. This continuous release method can avoid the fluctuation of blood drug concentration caused by oral drugs, and help maintain a more stable healing effect. The medical dressing is simple to use, does not require oral administration, and improves patient compliance.

[0016] The medical dressing of the present application has high water content, softness and good biocompatibility, which greatly improves the patient's acceptance and has a good healing effect.

[0017] In the preparation method of the present application, under the action of at least three ultrasonic treatments, the original molecular chains and hydrogen bond structures in the system can be broken up, and groups such as carboxyl groups in high molecular polymers such as carbomer can be promoted to combine with water and glycerol to form hydrogen bonds. The force generated by the hydrogen bonds will cause the curled high molecular chains to unwind in the aqueous solution. Applying it to the skin surface (solvent state coating) or applying it to the skin surface after drying (gel state coating) can form a stable hydrogel network, thereby locking in moisture and enhancing the water retention effect of the composition. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following briefly introduces the drawings required for use in the embodiments of the present application. Obviously, the drawings described below are only some implementation methods of the present application, and for ordinary technicians in this field, other drawings can be obtained based on the drawings without creative work.

[0019] Figure 1 A schematic diagram showing the effects before and after using the medical dressing of the present application provided in an embodiment of the present application is shown; wherein Figure 1 (a) is a schematic diagram showing the effect of the subject before using the medical dressing of the present application provided in some embodiments of the present application; Figure 1 (b) is a schematic diagram showing the effect of using the medical dressing of the present application provided in some embodiments of the present application. DETAILED DESCRIPTION

[0020] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.

[0021] In a first aspect, the present application provides a method for preparing a medical composition comprising polyglutamic acid, the method comprising: providing a first solution comprising purified water, glycerin, and carbomer; Mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and the first solution under heating conditions to obtain a third mixture; subjecting the third mixture to ultrasonic treatment and cooling at least three times to obtain a fourth mixed solution; Providing a second solution comprising purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol; The fourth mixed liquid is mixed with the second solution to obtain a medical composition, which includes, by mass percentage, the following: sodium hyaluronate: 0.1%-5%, glycerol: 2%-6%, carbomer: 0.35%-0.8%, hydroxyethyl cellulose: 0.3%-3.5%, polyglutamic acid: 0.1%-5%, trehalose: 1.8%-2.5%, recombinant human collagen: 0.1%-1%, benzyl alcohol: 0.5%-1.0%, β-glucan: 0.5%-5.0%, silicon nitride particles: 0.5%-1.5%, and the balance is purified water.

[0022] In the embodiments of the present application, polyglutamic acid is a natural biopolymer material produced by microbial fermentation, which has excellent biocompatibility and biodegradability, moisturizing and antibacterial effects; silicon nitride particles have excellent biocompatibility and safety in medical compositions, and have good antibacterial properties and biological activity; silicon nitride particles have physical pores to reduce the probability of inflammation. Benzyl alcohol is a compound with weak antibacterial properties that can inhibit the growth of bacteria to a certain extent, reduce the risk of wound infection, and interact with recombinant human collagen and β-glucan to promote wound healing and tissue repair. Benzyl alcohol is often used as a solvent to help dissolve and stabilize other whitening active ingredients, such as recombinant human collagen and β-glucan.

[0023] Trehalose in the present embodiment has a certain antioxidant effect, which can indirectly reduce the production of melanin; recombinant human collagen can repair the skin barrier and improve skin quality and skin color. β-glucan inhibits melanin formation by reducing inflammation, and has a certain indirect anti-inflammatory and whitening effect.

[0024] The medical composition of the present application has the above-mentioned ingredients and has a certain whitening effect on the basis of promoting wound healing.

[0025] The hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and the first solution are mixed under heating conditions. The heating temperature may be 60-75° C., which is beneficial to maintaining the dispersed state of each component and improving the uniform mixing degree of each substance.

[0026] In some embodiments, the medical composition includes, by mass percentage: sodium hyaluronate: 4%, glycerol: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β-glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

[0027] In some embodiments, the mass ratio of the fourth mixed solution to the second solution is 1:(0.5-2). Controlling the mass ratio of the fourth mixed solution to the second solution is beneficial to controlling the content of the active ingredient in the final medical composition and the uniform dispersion of the substance.

[0028] In some embodiments, the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles is 5:4:(0.8-1). Controlling the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles within the above range can make the medical composition have a certain whitening effect on the basis of promoting wound healing, and can also improve the stability of the medical composition.

[0029] In some embodiments, the medicinal composition is solvent-based.

[0030] In some embodiments, hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and the first solution are mixed under heating conditions at 25° C.-40° C. to obtain a third mixture.

[0031] In some embodiments, the fourth mixed solution is mixed with the second solution at 25°C-40°C.

[0032] In some embodiments, at least three ultrasonic treatments include: a first ultrasonic treatment, a second ultrasonic treatment and a third ultrasonic treatment in sequence; the temperature of the first ultrasonic treatment is 40-50°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 30-50kHz for 1-3 minutes; the temperature of the second ultrasonic treatment is 50-60°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 20-25kHz for 2-5 minutes; the temperature of the third ultrasonic treatment is 50-65°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 10-15kHz for 2-5 minutes.

[0033] In some embodiments, the third mixture is subjected to ultrasonic treatment and cooling at least three times to obtain a fourth mixed solution, comprising: The third mixture is subjected to ultrasonic treatment at least three times, and then vacuum is turned on for defoaming, and the defoaming time is 3-10 minutes; Then the mixture is cooled to 25-30° C. to obtain a fourth mixed solution.

[0034] In some embodiments, the viscosity of the fourth mixed solution is 100-600 cst. Controlling the viscosity of the fourth mixed solution within the above range can control the content of the active ingredient therein, which is beneficial for intuitively determining the stability and quality of the solution and is beneficial for improving the use effect of the medical composition.

[0035] In a second aspect, the present application provides a medical composition comprising polyglutamic acid, which is prepared by the preparation method of the first aspect.

[0036] The above-mentioned medical composition is solvent-based, convenient to use and has a refreshing feeling.

[0037] In a third aspect, the present application provides a medical dressing, which is obtained by drying the medical composition prepared by the preparation method of the first aspect, wherein the medical dressing is in a gel state and has a water content of 40%-60%.

[0038] After the prepared medical composition is dried, the water content of the medical dressing is 40%-60%. At this time, it is in a gel state and can be directly applied to the affected area in the form of a dressing, which is beneficial to promote wound healing and has a certain whitening effect. Example 1

[0039] This embodiment provides a method for preparing a medical composition, which contains the following components in the following mass parts: sodium hyaluronate: 4 parts, glycerol: 4 parts, carbomer: 0.6 parts, hydroxyethyl cellulose: 3.5 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human collagen: 1.0 parts, β-glucan: 4.0 parts, silicon nitride particles: 1.0 parts, benzyl alcohol: 0.8 parts, purified water: add to 100 parts. The preparation process is: (1) Solution preparation: Preparation 1: Heat and sterilize 1% purified water, then cool to room temperature for later use; Pre-production 2: Reserve 0.5 kg of water, heat and disinfect it, then cool it for later use. Use it as needed in the preparation process, such as flushing residual raw materials in the container; Preparation 3: Add 2% purified water, heat and sterilize, then cool to room temperature, add recombinant human collagen and completely dissolve for later use; Preparation 4: Add 1% purified water, heat and sterilize, then cool to room temperature, then add β-glucan and completely dissolve for later use; (2) Add purified water and glycerol into a water pot, add Carbomer-940 and soak until it is moistened, stir and heat to 75°C, stir to dissolve, and keep warm for 20 minutes to obtain a first solution; (3) Add hydroxyethyl cellulose, polyglutamic acid, trehalose, and silicon nitride particles into the pot in sequence, mix with the first solution, heat and stir to dissolve, raise the temperature to 40°C, and keep warm for 20 minutes; (4) The raw materials in the water pot are pumped into the emulsification pot and homogenized at a low speed for 3 minutes. The oil phase is pumped into the emulsification pot under rapid stirring, and ultrasound is turned on. Three ultrasonic treatments are performed in sequence. The temperature of the first ultrasonic treatment is 45°C, and the ultrasonic dispersion and emulsification are carried out at a frequency of 40 kHz for 2 minutes; the temperature of the second ultrasonic treatment is 60°C, and the ultrasonic dispersion and emulsification are carried out at a frequency of 23 kHz for 3 minutes; the temperature of the third ultrasonic treatment is 65°C, and the ultrasonic dispersion and emulsification are carried out at a frequency of 12 kHz for 4 minutes. At this time, the viscosity of the mixed liquid is 450 cst.

[0040] (5) Turn on the cooling water, cool down to 45°C, turn off the vacuum, add preformed 1, turn on the vacuum again, and stir for 20 minutes; (6) Prepare a second solution of purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol.

[0041] (7) Cool down to 40°C, turn off the vacuum, add preformed 3 and preformed 4, turn on the vacuum again, cool down to 38°C while stirring, stir for 40 minutes, cool to 25°C and mix with the second solution, complete the preparation, and fill the mixture into a pot to obtain a medical composition.

[0042] This embodiment provides a method for preparing a medical dressing, comprising: drying a medical composition to make the water content of the medical composition 50% to form a gel-state medical dressing.

[0043] Example 2 The difference between this embodiment and embodiment 1 is that the components of the medical composition are different. The medical composition includes, by weight: Sodium hyaluronate: 4 parts, glycerin: 2 parts, carbomer: 0.35 parts, hydroxyethyl cellulose: 3 parts, polyglutamic acid: 4.5 parts, trehalose: 2.5 parts, recombinant human collagen: 1.0 parts, β-glucan: 0.5 parts, silicon nitride particles: 0.5 parts, benzyl alcohol: 0.5 parts, purified water: add to 100 parts.

[0044] Example 3 The difference between this embodiment and embodiment 1 is that the components of the medical composition are different. The medical composition includes, by weight: Sodium hyaluronate: 4 parts, glycerin: 6 parts, carbomer: 0.8 parts, hydroxyethyl cellulose: 2.5 parts, polyglutamic acid: 3 parts, trehalose: 2.5 parts, recombinant human collagen: 0.29 parts, β-glucan: 5.0 parts, silicon nitride particles: 1.5 parts, benzyl alcohol: 1.0 parts, purified water: add to 100 parts.

[0045] Example 4 The difference between this embodiment and embodiment 1 is that the components of the medical composition are different. The medical composition includes, by weight: Sodium hyaluronate: 4 parts, glycerin: 4 parts, carbomer: 0.6 parts, hydroxyethyl cellulose: 3.0 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human collagen: 1.0 parts, β-glucan: 4.0 parts, silicon nitride particles: 1.0 parts, benzyl alcohol: 1 part, purified water: add to 100 parts.

[0046] Example 5 The difference between this embodiment and embodiment 1 is that the components of the medical composition are different. The medical composition includes, by weight: Sodium hyaluronate: 4 parts, glycerin: 4 parts, carbomer: 0.6 parts, hydroxyethyl cellulose: 2.5 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human collagen: 1.0 parts, β-glucan: 4.0 parts, silicon nitride particles: 1.0 parts, benzyl alcohol: 0.5 parts, purified water: add to 100 parts.

[0047] Example 6 The difference between this embodiment and embodiment 1 is that the ultrasonic treatment process is different. The temperature of the first ultrasonic treatment is 40°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 50kHz for 2 minutes; the temperature of the second ultrasonic treatment is 55°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 20kHz for 3 minutes; the temperature of the third ultrasonic treatment is 60°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 10kHz for 4 minutes. At this time, the viscosity of the mixed solution is 290cst.

[0048] Example 7 The difference between this embodiment and embodiment 1 is that the temperature of the first ultrasonic treatment is 50°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 30kHz for 2 minutes; the temperature of the second ultrasonic treatment is 55°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 25kHz for 4 minutes; the temperature of the third ultrasonic treatment is 65°C, and the ultrasonic dispersion and emulsification is carried out at a frequency of 10-15kHz for 2 minutes. At this time, the viscosity of the mixed solution is 314cst.

[0049] Comparative Example 1 The difference between this comparative example and Example 1 is that the components of the medical composition are different and the medical composition does not contain polyglutamic acid.

[0050] Comparative Example 2 The difference between this comparative example and Example 1 is that the components of the medical composition are different, and the medical composition does not contain recombinant human collagen and silicon nitride particles.

[0051] Comparative Example 3 The difference between this comparative example and Example 1 is that the components of the medical composition are different, the medical composition does not contain benzyl alcohol, and an equal mass of glycerol is used instead.

[0052] Comparative Example 4 The difference between this comparative example and Example 1 is that the frequency in the first, second and third ultrasonic treatments is 15 kHz, and the other steps are the same as those in Example 1. At this time, the viscosity of the mixed solution is 510 cst.

[0053] Comparative Example 5 The difference between this comparative example and Example 1 is that ethyl cellulose, polyglutamic acid, sodium hyaluronate, trehalose, and silicon nitride particles are sequentially added to the pot and mixed with the first solution and heated and stirred to dissolve, and the temperature is raised to 80° C. for mixing. The temperature of the second ultrasonic treatment is 80° C., and the third ultrasonic treatment is at 80° C. The viscosity of the mixed solution at this time is 590 cst.

[0054] Test Section 1) Stability test: The stability of the medical dressings obtained in Examples 1-7 and Comparative Examples 1-5 was tested in a high temperature and high humidity environment. The samples were placed in an environment with a temperature of 65°C and a humidity of 75%, and the dressings were observed and recorded. The medical dressings obtained in Examples 1-7 were highly stable in a high temperature and high pressure environment, and no delamination occurred after 90 days, and some samples did not delaminate even after 120 days. However, Comparative Examples 1-5 were not sufficiently dispersed and emulsified, and delaminated after about 60 days. The results are shown in Table 1.

[0055] The experiment showed that the medical dressings obtained in Examples 1-7 were highly stable under high temperature and high pressure, and no stratification occurred after 90 days, and some samples did not stratify even after 120 days. However, the dispersion and emulsification of Comparative Examples 1-5 were insufficient, and stratification occurred after about 60 days.

[0056] 2) Water retention capacity test: 10 g of each of the medical dressing samples prepared in Examples 1-7 and Comparative Examples 1-5 were placed in a culture dish, recorded as m0, and exposed to air at room temperature for a period of time. The mass of the samples was weighed at 6 h, 12 h, 24 h, and 72 h, recorded as mt. The percentage data of mt / m0 are shown in Table 1.

[0057] 3) Particle size and stability test: The medical dressings prepared in the examples and comparative examples were evaluated. An equal amount of the medical dressings was placed in a 100 ml sample tube, and the sample tube was placed in a 59°C oven for an accelerated test. The changes in the gel particle size (D99, μm) and state were examined using a laser particle size analyzer.

[0058] The test results are shown in Table 1.

[0059] Table 1

[0060] It can be seen from the data in the table that the medical dressing obtained by this method has excellent stability, but under the conditions of accelerated heating, the particle size of the medical dressing remains stable and has a good moisturizing effect. It also shows that the mixture of the medical dressing forms a gel, which can be stabilized at the nanometer level under appropriate control conditions and has a certain stability.

[0061] The subjects' initial state and 15 days after using the medical dressing of Example 1 were tested by a micro-A skin detector scanner. The results are as follows: Figure 1 As shown. The darker the color, the more red areas, indicating poor healing effect, and if the healing effect is good, the lighter the color. Figure 1 (a) is the initial situation when the medical dressing of Example 1 is not used, Figure 1 (b) shows the situation after using the medical dressing of Example 1 for 15 days, which illustrates that the medical dressing of the present application has certain whitening and healing effects.

[0062] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A method for preparing a medical composition comprising polyglutamic acid, characterized in that: The method comprises: providing a first solution comprising purified water, glycerin, and carbomer; Mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and the first solution under heating conditions to obtain a third mixture; subjecting the third mixture to ultrasonic treatment and cooling at least three times to obtain a fourth mixed solution; Providing a second solution comprising purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol; The fourth mixed liquid is mixed with the second solution to obtain the medical composition, which includes, by mass percentage, sodium hyaluronate: 0.1%-5%, glycerol: 2%-6%, carbomer: 0.35%-0.8%, hydroxyethyl cellulose: 0.3%-3.5%, polyglutamic acid: 0.1%-5%, trehalose: 1.8%-2.5%, recombinant human collagen: 0.1%-1%, benzyl alcohol: 0.5%-1.0%, β-glucan: 0.5%-5.0%, silicon nitride particles: 0.5%-1.5%, and the balance is purified water.

2. The preparation method according to claim 1, characterized in that: The medical composition comprises, by mass percentage: Sodium hyaluronate: 4%, glycerin: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β-glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

3. The preparation method according to claim 1, characterized in that: The mass ratio of the fourth mixed solution to the second solution is 1:(0.5-2).

4. The preparation method according to claim 1, characterized in that: The mass ratio of the polyglutamic acid, the β-glucan and the silicon nitride particles is 5:4:(0.8-1).

5. The preparation method according to claim 1, characterized in that: The medical composition is solvent-based.

6. The preparation method according to claim 1, characterized in that: The at least three ultrasonic treatments sequentially include: a first ultrasonic treatment, a second ultrasonic treatment and a third ultrasonic treatment; the first ultrasonic treatment is performed at a temperature of 40-50°C, and ultrasonic dispersion and emulsification is performed at a frequency of 30-50kHz for 1-3min; the second ultrasonic treatment is performed at a temperature of 50-60°C, and ultrasonic dispersion and emulsification is performed at a frequency of 20-25kHz for 2-5min; the third ultrasonic treatment is performed at a temperature of 50-65°C, and ultrasonic dispersion and emulsification is performed at a frequency of 10-15kHz for 2-5min.

7. The preparation method according to claim 1, characterized in that: The third mixture is subjected to ultrasonic treatment and cooling for at least three times to obtain a fourth mixed solution, comprising: The third mixture is subjected to ultrasonic treatment at least three times, and then vacuum is turned on for defoaming, and the defoaming time is 3-10 minutes; Then the mixture is cooled to 25-30° C. to obtain a fourth mixed solution.

8. The preparation method according to any one of claims 1 to 7, characterized in that: The viscosity of the fourth mixed liquid is 100-600 cst.

9. A medical composition comprising polyglutamic acid, characterized in that It is prepared by the preparation method according to any one of claims 1 to 7.

10. A medical dressing, characterized in that: The medical composition prepared by the preparation method according to any one of claims 1 to 7 is dried, wherein the medical dressing is in a gel state and has a water content of 40%-60%.

Images